149 related articles for article (PubMed ID: 36074125)
1. Venglustat Inhibits Protein N-Terminal Methyltransferase 1 in a Substrate-Competitive Manner.
Dong G; Deng Y; Yasgar A; Yadav R; Talley D; Zakharov AV; Jain S; Rai G; Noinaj N; Simeonov A; Huang R
J Med Chem; 2022 Sep; 65(18):12334-12345. PubMed ID: 36074125
[TBL] [Abstract][Full Text] [Related]
2. Structure-Activity Relationship Studies of Venglustat on NTMT1 Inhibition.
Deng Y; Dong G; Meng Y; Noinaj N; Huang R
J Med Chem; 2023 Jan; 66(2):1601-1615. PubMed ID: 36634151
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and kinetic analysis of potent protein N-terminal methyltransferase 1 inhibitors.
Zhang G; Richardson SL; Mao Y; Huang R
Org Biomol Chem; 2015 Apr; 13(14):4149-54. PubMed ID: 25712161
[TBL] [Abstract][Full Text] [Related]
4. Selective Peptidomimetic Inhibitors of NTMT1/2: Rational Design, Synthesis, Characterization, and Crystallographic Studies.
Mackie BD; Chen D; Dong G; Dong C; Parker H; Schaner Tooley CE; Noinaj N; Min J; Huang R
J Med Chem; 2020 Sep; 63(17):9512-9522. PubMed ID: 32689795
[TBL] [Abstract][Full Text] [Related]
5. Improved Cell-Potent and Selective Peptidomimetic Inhibitors of Protein N-Terminal Methyltransferase 1.
Dong G; Iyamu ID; Vilseck JZ; Chen D; Huang R
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209173
[TBL] [Abstract][Full Text] [Related]
6. Probing the Plasticity in the Active Site of Protein N-terminal Methyltransferase 1 Using Bisubstrate Analogues.
Chen D; Dong C; Dong G; Srinivasan K; Min J; Noinaj N; Huang R
J Med Chem; 2020 Aug; 63(15):8419-8431. PubMed ID: 32605369
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Bisubstrate Inhibitors for Protein N-Terminal Methyltransferase 1.
Chen D; Dong G; Noinaj N; Huang R
J Med Chem; 2019 Apr; 62(7):3773-3779. PubMed ID: 30883119
[TBL] [Abstract][Full Text] [Related]
8. Structure-based Discovery of Cell-Potent Peptidomimetic Inhibitors for Protein N-Terminal Methyltransferase 1.
Chen D; Dong G; Deng Y; Noinaj N; Huang R
ACS Med Chem Lett; 2021 Mar; 12(3):485-493. PubMed ID: 33738076
[TBL] [Abstract][Full Text] [Related]
9. Kinetic mechanism of protein N-terminal methyltransferase 1.
Richardson SL; Mao Y; Zhang G; Hanjra P; Peterson DL; Huang R
J Biol Chem; 2015 May; 290(18):11601-10. PubMed ID: 25771539
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for substrate recognition by the human N-terminal methyltransferase 1.
Dong C; Mao Y; Tempel W; Qin S; Li L; Loppnau P; Huang R; Min J
Genes Dev; 2015 Nov; 29(22):2343-8. PubMed ID: 26543161
[TBL] [Abstract][Full Text] [Related]
11. Chemoproteomic Study Uncovers HemK2/KMT9 As a New Target for NTMT1 Bisubstrate Inhibitors.
Chen D; Meng Y; Yu D; Noinaj N; Cheng X; Huang R
ACS Chem Biol; 2021 Jul; 16(7):1234-1242. PubMed ID: 34192867
[TBL] [Abstract][Full Text] [Related]
12. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1.
Zhou Q; Wu W; Jia K; Qi G; Sun XS; Li P
Eur J Med Chem; 2022 Dec; 244():114830. PubMed ID: 36228414
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.
Peterschmitt MJ; Crawford NPS; Gaemers SJM; Ji AJ; Sharma J; Pham TT
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):86-98. PubMed ID: 32851809
[TBL] [Abstract][Full Text] [Related]
14.
Jia K; Huang G; Wu W; Shrestha R; Wu B; Xiong Y; Li P
Chem Sci; 2019 Sep; 10(35):8094-8099. PubMed ID: 31857877
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model.
Viel C; Clarke J; Kayatekin C; Richards AM; Chiang MSR; Park H; Wang B; Shihabuddin LS; Sardi SP
Sci Rep; 2021 Oct; 11(1):20945. PubMed ID: 34686711
[TBL] [Abstract][Full Text] [Related]
16. The comprehensive analysis of the prognostic and functional role of N-terminal methyltransferases 1 in pan-cancer.
Tan L; Li W; Su Q
PeerJ; 2023; 11():e16263. PubMed ID: 37901469
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
Prat M; Buil MA; Fernández MD; Castro J; Monleón JM; Tort L; Casals G; Ferrer M; Huerta JM; Espinosa S; López M; Segarra V; Gavaldà A; Miralpeix M; Ramos I; Vilella D; González M; Córdoba M; Cárdenas A; Antón F; Beleta J; Ryder H
Bioorg Med Chem Lett; 2011 Jun; 21(11):3457-61. PubMed ID: 21524581
[TBL] [Abstract][Full Text] [Related]
18. Three's a crowd - why did three N-terminal methyltransferases evolve for one job?
Conner MM; Schaner Tooley CE
J Cell Sci; 2023 Jan; 136(2):. PubMed ID: 36647772
[TBL] [Abstract][Full Text] [Related]
19. An asparagine/glycine switch governs product specificity of human N-terminal methyltransferase NTMT2.
Dong C; Dong G; Li L; Zhu L; Tempel W; Liu Y; Huang R; Min J
Commun Biol; 2018; 1():183. PubMed ID: 30417120
[TBL] [Abstract][Full Text] [Related]
20. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
Schiffmann R; Cox TM; Dedieu JF; Gaemers SJM; Hennermann JB; Ida H; Mengel E; Minini P; Mistry P; Musholt PB; Scott D; Sharma J; Peterschmitt MJ
Brain; 2023 Feb; 146(2):461-474. PubMed ID: 36256599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
